293results about "Inactivation/attenuation" patented technology

The application discloses an isolation method of bovine epidemic fever virus and the bovine epidemic fever virus obtained by the method and application of the bovine epidemic fever virus, and belongs to the technical field of bovine epidemic fever virus isolation. The application aims to provide an efficient and rapid method for isolating bovine epidemic fever virus. The application provides the isolation method of the bovine epidemic fever virus, wherein the anticoagulated blood sample of a bovine is inoculated on KC cells for culture, the virus is harvested, the BHK-21 cells are inoculated to grow into a monolayer, and the first generation of passage cells with cytopathic effect is obtained by passage. The virus strain can also be used for screening, preparation and detection of bovine epidemic fever virus antibodies, and for preparation of an animal model infected by the bovine epidemic fever virus.

The invention relates to a genome large fragment deleted duck adenovirus B2 strain and application thereof, the duck adenovirus B2 strain is duck adenovirus B2 DAdV-B2 / delta ORF55-ORF19, and is preserved in China Center for Type Culture Collection on September 26, 2025, and the preservation number is CCTCC NO: V202568. Compared with the duck adenovirus B2 strain BGMH, the duck adenovirus B2 strain has a deletion region between ORF20 and ORF53 genes, and the duck adenovirus B2 strain is deleted by 7422 bp. According to the invention, the duck adenovirus B2 strain with the genome deleted in large fragment is found for the first time, and the deletion region of the virus is a good site for inserting an exogenous gene, so that the duck adenovirus B2 DAdV-B2 / delta ORF55-ORF19 can be used as a good virus vector to construct a recombinant virus, and the constructed recombinant virus can be stably inherited; the method can be applied to waterfowl novel recombinant virus vector vaccine research and development, waterfowl basic scientific research, gene virus vector delivery and the like, and has wide application prospect and value.

The present invention provides influenza viruses that exhibit enhanced growth in Vero cells. The influenza viruses include PB1, PB2, PA, NP, and NS gene segments that encode proteins having amino acid sequences that include selected amino acids. Optionally, at least one of the PB1, PB2, and PA gene segments includes a promoter cytosine to uracil mutation at nucleotide position 4. The present invention also provides pharmaceutical formulations containing the influenza viruses, methods for inducing an immune response in a mammal by administering the influenza viruses to a mammal, and methods for producing influenza viruses.

The invention provides a novel bovine nodular skin disease virus LSDV-125 strain and application thereof in vaccine preparation, and belongs to the technical field of virology. The problem that a novel vaccine strain which is clear in genetic background, stably weakened in virulence and capable of inducing broad-spectrum immune response is urgently needed is solved. The invention relates to a sheep pox virus strain, in particular to a sheep pox virus LSDV-125 which is named sheep pox virus LSDV-HLJ-2023, has the preservation number of CCTCC (China Center for Type Culture Collection) NO: V202537, and is preserved in China Center for Type Culture Collection on May 13, 2025. The method is mainly used for developing efficient and safe attenuated live vaccines.

The invention discloses an akabane virus inactivated vaccine preparation method, which comprises: carrying out Vero cell passage in a cell bottle, taking well growing cells until the cells grow to 80-90%, adding into a DMEM culture medium containing 10% of fetal calf serum, taking out the cells growing to 80-90% and having a good state, adding akabane virus CH-JL-01-2022 according to a volume ratio of 0.1%, and carrying out culture at a temperature of 80-90 DEG C so as to obtain the akabane virus inactivated vaccine. Culturing for 2-3 days in an incubator with the temperature of 37 DEG C and 5% CO2; the method comprises the following steps: preparing 0.25 M BEI, 0.1 M BPL and a 40% formaldehyde solution as inactivators, setting five concentration gradients according to the volume ratios of 0.01%, 0.05%, 0.1% and 0.5%, and collecting after 6 hours, 12 hours, 24 hours, 36 hours and 48 hours after adding; the screening of the akabane virus inactivation conditions according to the types, concentrations and inactivation time of inactivators finds that 0.5% formaldehyde shows a complete inactivation effect after inactivation for 36 hours. The inactivated virus liquid is mixed with MONTANIDETM ISA 201, an ImjectI aluminum adjuvant and a manganese adjuvant according to the volume ratio of 1: 1, and then immunization is carried out, and the protection effect of the ImjectI aluminum adjuvant is found to be optimal.

The invention relates to a preparation method of a Vero cell influenza virus vaccine, and belongs to the technical field of virus culture. In the culture of the influenza virus, red algae protein and soybean protein hydrolysate are added into a culture medium at the same time, the red algae protein and soybean protein hydrolysate are subjected to low-temperature ammonium sulfate precipitation and PD-10 desalination column purification, natural conformation is kept, integrin-FAK-Src and IGF-1R signal channels can be activated, and cell adhesion and proliferation are promoted; the latter contains soybean protein isolate, polysaccharide and RGD motif peptide, and can form an adhesion film on a substrate and mediate adhesion through integrin. According to the invention, the Vero cells and the recombinant plasmid are combined to improve cell adherence, metabolic homeostasis and oxidation resistance, so that the Vero cells grow at high density and efficiently replicate influenza viruses under a serum-free condition, the virus titer (TCID50) reaches 8.5 log10 / mL, and the Vero cells and the recombinant plasmid are suitable for industrial vaccine production.

The invention relates to an application of a THBS4 inhibitor in preparation of a medicine for preventing and / or treating pulmonary arterial hypertension. Three pulmonary arterial hypertension rat models (a hypoxia induction model, a hypoxia combined SUGEN induction model and a monocrotaline induction model) are constructed, the expression change of THBS4 is verified through qRT-PCR and western blot, and the correlation between the expression level of THBS4 and pulmonary arterial hypertension is verified in combination with in-vitro cell experiments and in-vivo intervention. Results show that THBS4 is remarkably up-regulated in pulmonary arteries of the three models, the expression level of THBS4 is positively correlated with the severity of diseases, and THBS4 is an important regulatory factor for promoting vascular remodeling in pulmonary arterial hypertension. In vivo, by knocking down THBS4, pulmonary vascular remodeling and right ventricular hypertrophy are remarkably relieved, and it is prompted that THBS4 inhibitors show good application prospects in the aspect of preventing and / or treating pulmonary arterial hypertension.

The invention belongs to the field of drug antivirus, and particularly discloses broad-spectrum antiviral application of punicalagin, the punicalagin has a structure shown in a formula 1, is good in stability and low in biological toxic and side effects, and can be used for developing novel broad-spectrum antiviral drugs.

Provided in the present application are an RNA-guided endonuclease system and the use thereof in gene editing. The endonuclease complex comprises an RNA-guided endonuclease and RNA, wherein the RNA-guided endonuclease comprises an amino acid sequence selected from SEQ ID NOs: 1-57 and SEQ ID NOs: 150-191, guide RNA comprises RNA associated with the RNA-guided endonuclease and targeting RNA, the RNA associated with the RNA-guided endonuclease comprises the sequence of any one of SEQ ID NOs: 58-114 and SEQ ID NOs: 192-233, and the targeting RNA is at the 3'-end of the RNA associated with the RNA-guided endonuclease and is identical or complementary to the targeting sequence of a genome of interest. The endonuclease complex of the present application can be used for efficient gene cleavage and gene editing.

A CD1 peptide-epitope for use in the treatment of a disease causedby an intracellular pathogen, the method for the identification ofthis CD1 peptide epitope, the pharmaceutical kit comprising thisCD1 peptide epitope and the method to treat a patient against adisease caused by an intracellular pathogen or to prevent suchinfection, based on vaccination with this CD1 peptide-epitope.

The present invention provides materials and methods for viral engineering, including materials and methods for producing vectors and viral particles useful, for example, for gene therapy.

The high pathogenicity of the rift valley fever virus limits the research on the pathogenic mechanism and prevention, control and treatment products of the rift valley fever virus, the offspring replication-deficient virus particles are successfully saved through a reverse genetic manipulation technology, and the virus particles do not have the capacity of multiple rounds of infection on common cells; stable replication and passage can only be realized in a cell line for providing exogenous envelope glycoprotein; in addition, the virus particle carries an exogenous indication protein and can indicate cell infection. The Rift Valley fever virus-like particle provided by the invention can be used as a Rift Valley fever biosafety secondary laboratory research platform, the establishment of the virus particle greatly simplifies tedious procedures in the Rift Valley fever virus research process, and paves a way for screening of Rift Valley fever virus neutralizing antibodies, research and development of candidate vaccines and research of pathogenic mechanisms of the Rift Valley fever viruses.

The invention discloses a porcine circovirus type 2 and haemophilus parasuis bivalent inactivated vaccine and a preparation method thereof. According to the invention, a porcine circovirus strain, a haemophilus parasuis serum type 4 strain and a haemophilus parasuis serum type 5 strain which are epidemic in situ are respectively separated and obtained, and the microbial preservation numbers of the porcine circovirus strain, the haemophilus parasuis serum type 4 strain and the haemophilus parasuis serum type 5 strain are respectively CGMCC (China General Microbiological Culture Collection Center) No.47094, CGMCC No.46698 and The separated strain or bacterial strain is prepared into a bivalent inactivated vaccine, and lentinan is added in the vaccine preparation process to enhance the immune effect; a safety evaluation result shows that local or whole-body adverse reaction caused by the bivalent vaccine does not occur, so that the safety of the bivalent vaccine is good; the immune efficacy evaluation result of the bivalent vaccine shows that the bivalent vaccine can provide complete protection for animals aiming at the in-situ epidemic porcine circovirus, haemophilus parasuis serotype 4 and haemophilus parasuis serotype 5, and has good immune protection efficacy.

A cassette for the delivery of one or more mRNA is provided, the cassette comprising a 5' UTR, a Nodamura replicon, a ribosomal skipping polynucleotide, the one or more mRNA, a plant virus assembly origin polynucleotide ("OAS"), and a 3' UTR. In one aspect, the cassette further comprises a 5'mRNA cap. In a yet further aspect, the cassette does not comprise a poly A tail.

The invention belongs to the technical field of biology, and particularly relates to an attenuated porcine epidemic diarrhea virus recombinant strain, a construction method and application. According to the invention, amino acid N at the 381th site of PEDV S protein is mutated into K, and a recombinant strain rPEDV-SN381K is obtained through rescue; compared with a parent wild virus rPEDV-Swt, the recombinant virus strain rPEDV-SN381K has the advantages that the virulence of the recombinant virus strain rPEDV-SN381K is obviously weakened, the infection of the rPEDV-Swt can be effectively resisted, and the recombinant virus strain rPEDV-SN381K can be used for preparing a PEDV vaccine.

The invention provides a cell strain for producing engineered viroid particles, a method thereof and the engineered viroid particles, the cell strain is named as SZCV-Con28 and preserved in Guangdong Microbial Culture Collection Center on October 15, 2025, the preservation number is GDMCC No: 67101, and the preservation number is GDMCC No: 67101. A plurality of corresponding cell factories for producing the engineered viroid particles are established by cell lines obtained by introducing different target gRNA elements into the cell strain, so that the corresponding engineered viroid particles can be continuously produced in batches. According to the invention, large-scale preparation can be realized through cell expanding culture, the capacity limitation is overcome, the production process flow is simplified, and the consumption of production raw materials is reduced.

Disclosed herein are vaccine constructs for producing a virus-like particle (VLP) capable of raising an immune response to an immunogen, and uses thereof, wherein the constructs comprise nucleic acid sequences encoding an immunogen and a polyprotein, wherein the polyprotein comprises two or more viral structural proteins, wherein at least two of the two or more viral structural proteins are separated by a signal peptidase sequence such that, when the polyprotein is expressed in a host cell, the signal peptidase sequence undergoes host cell peptidase-dependent cleavage to liberate the two or more viral structural proteins, thereby allowing the liberated structural proteins to self-assemble into a VLP carrying the immunogen.

The present invention provides for modified Flavivirus such as a modified dengue virus type 1, 2, 3, 4, a combination of these, or a tetravalent combination of these. The modification according to various aspects of the invention results in reduced viral protein expression compared to a parent virus, wherein the reduction in expression is the result of recoding one or more regions of the virus. For example, the prM, or envelope (E) region can be recoded. In various embodiments one or more regions are recoded by reducing the codon pair bias or codon usage bias of the protein-encoding sequence. These modified Flaviviruses are used as vaccine compositions to provide a protective immune response.

Provided is a method for deactivating or removing viruses in a protein solution, the method including a step in which radiation treatment and virus removal membrane treatment or SD treatment are integrated and the conditions of these treatments are optimized to be mutually complementary. More specifically, the method includes: (a) a step in which a protein solution is treated by being irradiated with radiation so that the removal coefficient (LRV) for viruses with a virus particle diameter of less than 33 nm in the protein solution is at least 1.00; and (b1) a step in which viruses are removed from the treated protein solution by a virus removal membrane with an LRV of at least 4.00 for bacteriophage PP7, or (b2) a step in which the treated protein solution is brought into contact with a liquid mixture (SD liquid mixture) of an organic solvent and a surfactant and viruses are deactivated by organic solvent / surfactant treatment (SD treatment) so that the LRV for envelope viruses in the protein solution is at least 2.00. Also provided is a method for manufacturing a protein solution in / from which viruses have been deactivated / removed, the method including the abovementioned steps.

The invention discloses a recombinant antigen protein, a recombinant vector, a recombinant host cell, a virus-like particle and application thereof and a vaccine, and relates to the technical field of antigen preparation, the recombinant antigen protein comprises an icosahedral porcine circovirus capsid protein and an A104R protein loaded on the surface of the icosahedral porcine circovirus capsid protein, the A104R protein comprises a protein coded by an African swine fever virus A104R gene. The recombinant antigen protein capable of simultaneously reacting with positive serum of the African swine fever virus and positive serum of the porcine circovirus is prepared, and the vaccine prepared by mixing the recombinant antigen protein with an adjuvant can effectively stimulate a pig body to generate specific antibodies of the African swine fever virus and the porcine circovirus; therefore, reference is provided for joint defense of the two viruses. The recombinant antigen protein provided by the invention has the characteristics of stable expression, high yield and high solubility.

The disclosure provides for recombinantly modified Zika-based vectors that can be used in gene therapy applications.

The present invention relates to the field of biomedicine, and more particularly to a method for purifying an inactivated rabies virus vaccine. The method comprises the following steps: preparing an inactivated rabies virus ultrafiltration concentrate: purifying the inactivated rabies virus ultrafiltration concentrate by chromatography; the chromatography purification specifically comprises the following steps: column cleaning: loading a composite filler into a chromatography column, connecting an AKTA to the chromatography column, cleaning, sterilizing, and setting aside; chromatography operation: equilibrating the chromatography column with PBS buffer; sample loading: loading the inactivated rabies virus ultrafiltration concentrate into the chromatography column, eluting with an eluent, and collecting the eluate corresponding to the absorption peak at an ultraviolet wavelength of 280 nm, which is the purified inactivated rabies virus vaccine; column cleaning; and results showing that the residual protein content is as low as 5.0 ng / ml, the antigen content can reach above 16.0 IU / ml, the host protein removal rate can reach above 99%, and the antigen content recovery rate can reach above 86%.

It provides a vaccine platform that can be tailored to target any tumor type and appropriately stimulates the expansion of specific anti-tumor immune cells. [Solution] Provided are self-assembling pharmaceutical compositions comprising a heat shock protein fused to a biotin-binding protein, wherein the biotin-binding protein is non-covalently bound to a biotinylated component (e.g., a tumor cell, a tumor antigen, a virus, or a viral antigen). The self-assembling pharmaceutical compositions can further comprise an immunotherapy (e.g., an anti-PD-1 antibody). Also provided are methods of using these pharmaceutical compositions for preventing and / or treating cancer or inducing an immune response. Also provided are methods of using the self-assembling pharmaceutical compositions in combination with immunotherapy (e.g., an anti-PD-1 antibody).

The present invention relates to modified live porcine reproductive and respiratory syndrome viruses. The viruses were genetically analyzed and selected based on phylogenetic classification for modification by repeated passage in tissue culture. The modified live viruses were evaluated for their ability to confer protective immunity to heterologous viruses. The modified live viruses are useful in vaccines, particularly vaccines capable of treating infection of pigs with multiple heterologous viruses.

The invention relates to an immune system humanized mouse biological system for preparing a fully humanized monoclonal antibody and a method for preparing the fully humanized monoclonal antibody. The method comprises the following steps: using a constructed immune system humanized mouse and a VLP chimeric antigen; the HSC immune system humanized mouse is an immunodeficient mouse transplanted with human immune cells, the human immune cells are reconstructed, and antigen-specific B cells and fully humanized antibodies can be generated in the immune system humanized mouse by using a VLP chimeric antigen without firstly activating DC and antigen-specific T cells. In addition, by coupling a VLP antigen and a target antigen, a specific B cell and a fully human antibody of any target can be generated.

Described herein are Zika virus vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.

The application discloses a preparation method of a tetravalent influenza virus split vaccine and belongs to the technical field of vaccines. The preparation method of the tetravalent influenza virus split vaccine comprises the following steps: pre-incubation of a chicken embryo, pre-embryo inspection, virus inoculation and culture, post-embryo inspection, cold embryo, virus harvesting, ultrafiltration clarification, zone centrifugation, desugaring, chromatography, virus splitting, virus inactivation, ultrafiltration liquid replacement, sterilization filtration and preparation of a tetravalent influenza virus split vaccine product. Compared with the prior art, the technical means adopted in the application effectively reduces the content of free formaldehyde and improves the antibody level of the vaccine.

The invention discloses a porcine epidemic diarrhea virus G2c genotype strain as well as a separation method and application thereof. Aiming at the current epidemic PEDV variant strain, the genetic variation rule of the epidemic strain is clarified by carrying out virus separation, identification and pathogenicity analysis, and the method has important significance on epidemiology, vaccine development and the like of the PEDV. Specifically, an applicant successfully separates a PEDV strain capable of realizing stable passage propagation in Vero-CCL81 cells from intestinal contents of diarrhea piglets collected from a pig farm of Jiangpermanent Province in Hunan, the PEDV strain is identified and determined as a porcine epidemic diarrhea virus G2c subtype, the PEDV strain is named PEDV CH / HNJY / 2025, the PEDV strain is preserved in China General Microbiological Culture Collection Center on December 11, 2025, and the preservation number of the PEDV strain is CGMCC NO. The preservation number is CGMCC (China General Microbiological Culture Collection Center)

The present disclosure relates to the field of biotechnology, in particular to a method for virus production. The present disclosure improves the culture method to improve the virus titer.